We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Luminex Corporation reported third-quarter 2019 loss of 12 cents per share (EPS), significantly wider than the Zacks Consensus Estimate of 3 cents per share. Notably, the company reported earnings of 4 cents per share in the year-ago quarter.
Revenues in Detail
Revenues came in at $78.7 million, missing the Zacks Consensus Estimate by 3.9%. However, the top line improved 8.6% on a year-over-year basis.
Total sample-to-answer franchise revenues grew 27% from the prior-year quarter.
Luminex Corporation Price, Consensus and EPS Surprise
Revenues at this segment totaled $15.2 million, surging 52% from the year-ago quarter.
Consumable Sales
This segment accounted for $13.4 million of revenues, up 14.9% year over year.
Royalty Revenues
Royalty revenues totaled $12.9 million, up 7.5% on a year-over-year basis.
Assay Revenues
This segment reported revenues worth $29.5 million, down 12.7% on a year-over-year basis.
Service Revenues
Revenues in the segment amounted to $5.3 million, up 77.4% from the year-ago quarter.
Other
Other revenues came in at $2.3 million, up 16.2% from a year ago.
Business Details
Per management, this Texas-based company placed 31 sample-to-answer molecular systems under contract during the third quarter. Active sample-to-answer customers totaled 650 in the quarter under review.
Financial Update
As of Sep 30, 2019, cash and cash equivalents totaled $66.1 million, down 4.4% sequentially.
Cash flow from operating activities for the three months ended Sep 30, 2019, came in at $9.4 million, down 37.7% from the year-ago quarter.
Margins
Gross profit in the reported quarter was $41.8 million, down 5.5% year over year. Gross margin was 53.2%, contracting 790 bps.
Research and development expenses totaled $13.3 million, up 10.6% year over year. Selling, general and administrative expenses in the third quarter were $31.4 million, up 19.4% year over year. Total operating expenses amounted to $47.6 million, up 17.4% from the year-ago reported figure.
The company incurred operating loss of $5.7 million, against the year-ago quarter’s operating income of $3.8 million.
Guidance Revised
The company revised 2019 revenue outlook, which is now estimated to range between $334 and $337 million (down from the previously guided range of $337-$343 million). The mid-point of the latest guidance of $335.5 million is slightly lower than the Zacks Consensus Estimate of $340.6 million.
In Conclusion
Luminex exited the third quarter on a weak note. The company continues to gain from its flagship ARIES and VERIGENE platforms that currently have a strong customer base. Revenues at System sales, Consumable Sales and Service revenues also improved significantly. Management remains optimistic about the acquisition of the flow cytometry asset of MilliporeSigma.
During the third quarter, ARIES MRSA Assay received FDA 510(k) clearance. Moreover, the company submitted VERIGENE II Gastrointestinal Flex Assay to the FDA and anticipates submitting VERIGENE II Respiratory Flex Assay to the FDA by the end of 2019.
Meanwhile, the company’s assay revenues declined in the reported quarter. Contraction in gross margin adds to woes.
Zacks Rank
Currently, Luminex carries a Zacks Rank #3 (Hold).
Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Third-quarter net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which surpassed the Zacks Consensus Estimate by 2.1%. Revenues of $6.27 billion outpaced the Zacks Consensus Estimate by 1.3%.
ResMed reported third-quarter 2019 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Luminex (LMNX) Reports Q3 Loss, Misses Revenue Estimates
Luminex Corporation reported third-quarter 2019 loss of 12 cents per share (EPS), significantly wider than the Zacks Consensus Estimate of 3 cents per share. Notably, the company reported earnings of 4 cents per share in the year-ago quarter.
Revenues in Detail
Revenues came in at $78.7 million, missing the Zacks Consensus Estimate by 3.9%. However, the top line improved 8.6% on a year-over-year basis.
Total sample-to-answer franchise revenues grew 27% from the prior-year quarter.
Luminex Corporation Price, Consensus and EPS Surprise
Luminex Corporation price-consensus-eps-surprise-chart | Luminex Corporation Quote
Segmental Analysis
System Sales
Revenues at this segment totaled $15.2 million, surging 52% from the year-ago quarter.
Consumable Sales
This segment accounted for $13.4 million of revenues, up 14.9% year over year.
Royalty Revenues
Royalty revenues totaled $12.9 million, up 7.5% on a year-over-year basis.
Assay Revenues
This segment reported revenues worth $29.5 million, down 12.7% on a year-over-year basis.
Service Revenues
Revenues in the segment amounted to $5.3 million, up 77.4% from the year-ago quarter.
Other
Other revenues came in at $2.3 million, up 16.2% from a year ago.
Business Details
Per management, this Texas-based company placed 31 sample-to-answer molecular systems under contract during the third quarter. Active sample-to-answer customers totaled 650 in the quarter under review.
Financial Update
As of Sep 30, 2019, cash and cash equivalents totaled $66.1 million, down 4.4% sequentially.
Cash flow from operating activities for the three months ended Sep 30, 2019, came in at $9.4 million, down 37.7% from the year-ago quarter.
Margins
Gross profit in the reported quarter was $41.8 million, down 5.5% year over year. Gross margin was 53.2%, contracting 790 bps.
Research and development expenses totaled $13.3 million, up 10.6% year over year. Selling, general and administrative expenses in the third quarter were $31.4 million, up 19.4% year over year. Total operating expenses amounted to $47.6 million, up 17.4% from the year-ago reported figure.
The company incurred operating loss of $5.7 million, against the year-ago quarter’s operating income of $3.8 million.
Guidance Revised
The company revised 2019 revenue outlook, which is now estimated to range between $334 and $337 million (down from the previously guided range of $337-$343 million). The mid-point of the latest guidance of $335.5 million is slightly lower than the Zacks Consensus Estimate of $340.6 million.
In Conclusion
Luminex exited the third quarter on a weak note. The company continues to gain from its flagship ARIES and VERIGENE platforms that currently have a strong customer base. Revenues at System sales, Consumable Sales and Service revenues also improved significantly. Management remains optimistic about the acquisition of the flow cytometry asset of MilliporeSigma.
During the third quarter, ARIES MRSA Assay received FDA 510(k) clearance. Moreover, the company submitted VERIGENE II Gastrointestinal Flex Assay to the FDA and anticipates submitting VERIGENE II Respiratory Flex Assay to the FDA by the end of 2019.
Meanwhile, the company’s assay revenues declined in the reported quarter. Contraction in gross margin adds to woes.
Zacks Rank
Currently, Luminex carries a Zacks Rank #3 (Hold).
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks that reported solid results this earning season are Edwards Lifesciences (EW - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and ResMed Inc. (RMD - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Third-quarter net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which surpassed the Zacks Consensus Estimate by 2.1%. Revenues of $6.27 billion outpaced the Zacks Consensus Estimate by 1.3%.
ResMed reported third-quarter 2019 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>